Quintero L J, Lohre J M, Hernandez N, Meyer S C, McCarthy T J, Lin D S, Shen S H
Baxter Healthcare Corporation, Irvine, CA 92614, USA.
J Heart Valve Dis. 1998 May;7(3):262-7.
A common frame of reference is essential when attempting to determine if new treatments intended to reduce calcification of bioprostheses are superior to existing processes and products. The aim of this study was to examine calcification behavior for a commercially available pericardial bioprosthesis in subcutaneous and sheep valve models, and to evaluate the importance of appropriate control treatments in comparative studies with proposed new treatments.
Samples of bovine pericardium were placed subcutaneously under the dorsal skin of weanling rats and juvenile rabbits for 30-, 60- and 90-day intervals. Samples were either commercially available pericardial tissue or tissue processed with phosphate-buffered glutaraldehyde alone. Commercially available pericardial valves were also implanted in the mitral position in juvenile sheep, with elective sacrifice at 20 weeks. Retrieved samples underwent X-ray, histologic and elemental analysis.
Commercial samples retrieved from the subcutaneous and sheep models showed similar, minimal calcification behavior on X-ray and histologic slides, whereas pericardium exposed to glutaraldehyde alone demonstrated rapid calcification.
The 90-day subcutaneous rabbit model produced patterns of calcification similar to those in valves explanted from juvenile sheep after 20 weeks. A statistically significant decrease (p < 10(-8)) in calcification was demonstrated for clinical pericardium when compared with pericardium exposed to glutaraldehyde alone in the subcutaneous model. This suggests that subcutaneous models may be a cost-effective, time-efficient means of evaluating and comparing various tissue treatment methods. The rabbit methodology may provide a more accurate prediction of clinical performance, offering a greater degree of sensitivity. These studies also indicate that the commercially available process shows minimal calcification in the commonly used 30-day weanling rat subcutaneous model, contradicting other reported studies that may not accurately represent commercially available processes.
在试图确定旨在减少生物假体钙化的新治疗方法是否优于现有工艺和产品时,一个共同的参考框架至关重要。本研究的目的是在皮下和绵羊瓣膜模型中检查一种市售心包生物假体的钙化行为,并评估在与提议的新治疗方法的比较研究中适当对照治疗的重要性。
将牛心包样本皮下置于断奶大鼠和幼年兔子的背部皮肤下,分别放置30天、60天和90天。样本要么是市售心包组织,要么是仅用磷酸盐缓冲戊二醛处理的组织。还将市售心包瓣膜植入幼年绵羊的二尖瓣位置,20周后选择性处死。取出的样本进行X射线、组织学和元素分析。
从皮下和绵羊模型中取出的市售样本在X射线和组织学切片上显示出相似的、最小程度的钙化行为,而仅暴露于戊二醛的心包则表现出快速钙化。
90天的皮下兔子模型产生的钙化模式与20周后从幼年绵羊身上取出的瓣膜相似。与皮下模型中仅暴露于戊二醛的心包相比,临床心包的钙化有统计学意义的显著降低(p < 10(-8))。这表明皮下模型可能是评估和比较各种组织处理方法的一种经济有效、节省时间的手段。兔子实验方法可能对临床性能提供更准确的预测,具有更高的敏感性。这些研究还表明,市售工艺在常用的30天断奶大鼠皮下模型中显示出最小程度的钙化,这与其他可能未准确代表市售工艺的报道研究相矛盾。